IMD 1041

Drug Profile

IMD 1041

Alternative Names: IMD-1041

Latest Information Update: 28 May 2013

Price : $50

At a glance

  • Originator Institute of Medicinal Molecular Design
  • Class Anti-inflammatories; Small molecules
  • Mechanism of Action I-kappa B kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Chronic obstructive pulmonary disease

Most Recent Events

  • 28 May 2013 No development reported - Phase-II for Chronic obstructive pulmonary disease in United Kingdom (PO)
  • 28 May 2013 IMD 1041 is available for licensing as of 28 May 2013.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top